Supernus Pharmaceuticals, Inc. entered a definitive agreement to acquire Adamas Pharmaceuticals, Inc. for approximately $400 million, plus two non-tradable contingent value rights (CVR) collectively worth up to approximately $50 million, based on GOCOVRI sales. The second CVR is payable upon achieving sales of GOCOVRI of $225 million in any four consecutive quarters between closing and the end of 2025. The transaction is expected to close in late 2021 or early 2022.   The transaction provides ...